Whelan Pharmaceuticals, a U.S. company with $ 3 billion in sales, to decide where the production of its newest product. In considering possible sites, both foreign and U.S., the firm must identify and compromise between tax, marketing, and production factors. "Hide
by G. Peter Wilson, Jane Palley Katz Source: Harvard Business School 12 pages. Publication Date: November 13, 1991. Prod. #: 192066-PDF-ENG
Related Case Solutions & Analyses:
bp and Corporate Greenwash
Weighing Career Choices
Your Home is a Good Place Inc.
Chateau dAgel (A): From Concept to Deal
Glass Egg Digital Media
WaveRider Communications Inc.: The Wireless Last Mile
Apple vs. Samsung: The $2 Billion Case
Shanghai NSE Electric Co. Ltd. and Its International Cooperation
State Bank of India: Transforming a State Owned Giant
Customer Loyalty Schemes in the Retail Sector
